Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00962845 | Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | completed | Early Phase 1 | 20 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05054062 | Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients(TRACIE) | completed | N/A | 6 | Zuyderland Medisch CentrumOTHER | 1 | Sep 7, 2022 |
| clinicaltrials |
| NCT04680182 | Early Complications After Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients | completed | N/A | 104 | Oslo University HospitalOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT02843386 | Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma(FOTEADJ) | completed | Phase 3 | 302 | Institut CurieOTHER | 2 | Aug 31, 2022 | clinicaltrials |
| NCT03655756 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | completed | Early Phase 1 | 7 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT01835145 | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT04698161 | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic Diseases(BIOMIS-Onco) | completed | — | 50 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di BariOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02644967 | A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma | completed | Phase 2 | 53 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 3, 2022 | clinicaltrials |
| NCT03084640 | Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma | completed | Phase 1 | 30 | Regeneron PharmaceuticalsINDUSTRY | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02130466 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | completed | Phase 1 / Phase 2 | 184 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2022 | clinicaltrials |
| NCT02857374 | Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy | completed | N/A | 20 | Roswell Park Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT01896778 | Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer | completed | N/A | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03297424 | A Study of PLX2853 in Advanced Malignancies. | completed | Phase 1 | 49 | Opna Bio LLCINDUSTRY | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05463510 | Dermoscopic Monitoring of Pediatric Melanocytic Nevi Regarding Pattern and Diameter Changes | completed | — | 50 | Istanbul Training and Research HospitalOTHER_GOV | 1 | Jul 19, 2022 | clinicaltrials |
| NCT01721772 | Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma(CheckMate 066) | completed | Phase 3 | 418 | Bristol-Myers SquibbINDUSTRY | 16 | Jul 12, 2022 | clinicaltrials |
| NCT05115006 | A Study of Adjuvant Melanoma Stakeholder Treatment Preferences | completed | — | 294 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 30, 2022 | clinicaltrials |
| NCT00068172 | Study of PI-88 in Patients With Advanced Melanoma | completed | Phase 1 / Phase 2 | 88 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT00073892 | PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 44 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 27, 2022 | clinicaltrials |
| NCT02714218 | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | completed | Phase 3 | 387 | Bristol-Myers SquibbINDUSTRY | 13 | Jun 24, 2022 | clinicaltrials |
| NCT00130442 | Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma | completed | Phase 2 | 134 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 23, 2022 | clinicaltrials |
| NCT05426239 | Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database | completed | — | 1,008 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02434354 | A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma | completed | Phase 1 | 33 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03174574 | Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.(TCOG) | completed | — | 3 | Mayo ClinicOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT00602576 | Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 169 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05027009 | Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer | completed | N/A | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT02780089 | Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study | completed | — | 408 | Bristol-Myers SquibbINDUSTRY | 1 | May 23, 2022 | clinicaltrials |
| NCT05148455 | Pregnancy-related Changes in Melanocytic Nevi | completed | — | 50 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02376920 | 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes(CLEAR) | completed | — | 93 | Castle Biosciences IncorporatedINDUSTRY | 0 | May 16, 2022 | clinicaltrials |
| NCT00297895 | Multicenter Selective Lymphadenectomy Trial II (MSLT-II) | completed | N/A | 1,939 | Saint John's Cancer InstituteOTHER | 12 | May 13, 2022 | clinicaltrials |
| NCT01689519 | A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma(coBRIM) | completed | Phase 3 | 495 | Hoffmann-La RocheINDUSTRY | 19 | May 2, 2022 | clinicaltrials |
| NCT01721746 | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | completed | Phase 3 | 405 | Bristol-Myers SquibbINDUSTRY | 14 | Apr 19, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT01213732 | Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma | completed | Phase 1 | 19 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT00084656 | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | completed | Phase 2 | 77 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2022 | clinicaltrials |
| NCT01127451 | Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma | completed | Phase 2 | 75 | Eisai Inc.INDUSTRY | 1 | Apr 13, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT01904123 | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | completed | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT02626962 | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma(GEM1402) | completed | Phase 2 | 52 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT01927419 | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma(CheckMate 069) | completed | Phase 2 | 142 | Bristol-Myers SquibbINDUSTRY | 2 | Mar 18, 2022 | clinicaltrials |
| NCT05087485 | Integrated Basic Science Within the Instructional Design of Pattern Recognition Training(AISC-ISF) | completed | N/A | 87 | Herlev HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT01460810 | Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma | completed | N/A | 20 | University of Colorado, DenverOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT03197636 | Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients | completed | — | 40 | Aarhus University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02717364 | Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma | completed | — | 556 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 28, 2022 | clinicaltrials |
| NCT04154163 | Appropriate Dosing to Optimise Personalised Cancer Treatments(ADOPT) | completed | — | 18 | University of DundeeOTHER | 1 | Feb 28, 2022 | clinicaltrials |
| NCT01959633 | Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation(VEMUPLINT) | completed | Phase 1 / Phase 2 | 11 | Fondazione Melanoma OnlusOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04062032 | Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma | completed | Phase 2 | 41 | University of UtahOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT04066725 | Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma | completed | Phase 2 | 95 | University of UtahOTHER | 1 | Feb 18, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 7, 2022source: clinicaltrials